TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1752
AB  - Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
VL  - 45
IS  - 7-8
SP  - 547
EP  - 551
DO  - 10.1016/j.clinbiochem.2012.02.015
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention",
volume = "45",
number = "7-8",
pages = "547-551",
doi = "10.1016/j.clinbiochem.2012.02.015"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 45(7-8), 547-551.
https://doi.org/10.1016/j.clinbiochem.2012.02.015

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Ignjatović S, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry. 2012;45(7-8):547-551.
doi:10.1016/j.clinbiochem.2012.02.015 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention" in Clinical Biochemistry, 45, no. 7-8 (2012):547-551,
https://doi.org/10.1016/j.clinbiochem.2012.02.015 . .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mihailović, Mirjana
AU  - Nikolajević, Ivica
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1701
AB  - Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 1-2
SP  - 125
EP  - 131
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1701
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Majkić-Singh, Nada and Ignjatović, Svetlana and Mihailović, Mirjana and Nikolajević, Ivica and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "1-2",
pages = "125-131",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1701"
}

Stanković, S., Ašanin, M., Majkić-Singh, N., Ignjatović, S., Mihailović, M., Nikolajević, I., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(1-2), 125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701

Stanković S, Ašanin M, Majkić-Singh N, Ignjatović S, Mihailović M, Nikolajević I, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(1-2):125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

Stanković, Sanja, Ašanin, Milika, Majkić-Singh, Nada, Ignjatović, Svetlana, Mihailović, Mirjana, Nikolajević, Ivica, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 1-2 (2012):125-131,
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Miljković, Aleksandar
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1687
AB  - Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 11-12
SP  - 1135
EP  - 1144
DO  - 10.7754/Clin.Lab.2012.111102
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Miljković, Aleksandar and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "11-12",
pages = "1135-1144",
doi = "10.7754/Clin.Lab.2012.111102"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Miljković, A., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Ostojić, M.,& Vasiljević, Z.. (2012). Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(11-12), 1135-1144.
https://doi.org/10.7754/Clin.Lab.2012.111102

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Miljković A, Ignjatović S, Mrdović I, Matić D, Savić L, Ostojić M, Vasiljević Z. Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(11-12):1135-1144.
doi:10.7754/Clin.Lab.2012.111102 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Miljković, Aleksandar, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Ostojić, Miodrag, Vasiljević, Zorana, "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 11-12 (2012):1135-1144,
https://doi.org/10.7754/Clin.Lab.2012.111102 . .

TY  - JOUR
AU  - Beletić, Anđelo
AU  - Mirković, Duško
AU  - Antonijević, Nebojša
AU  - Đorđević, Valentina
AU  - Sango, Violeta
AU  - Jakovljević, Branko
AU  - Perunicić, Jovan
AU  - Ilić, Mirka
AU  - Vasiljević, Zorana
AU  - Majkić-Singh, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1168
AB  - Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 mu mol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P = 0.038). Median homocysteine levels in patients (10.4 mu mol/L) and controls (9.6 mu mol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from the observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction
VL  - 28
IS  - 1
SP  - 41
EP  - 45
DO  - 10.2478/v10011-008-0029-9
ER  - 

@article{
author = "Beletić, Anđelo and Mirković, Duško and Antonijević, Nebojša and Đorđević, Valentina and Sango, Violeta and Jakovljević, Branko and Perunicić, Jovan and Ilić, Mirka and Vasiljević, Zorana and Majkić-Singh, Nada",
year = "2009",
abstract = "Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 mu mol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P = 0.038). Median homocysteine levels in patients (10.4 mu mol/L) and controls (9.6 mu mol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from the observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction",
volume = "28",
number = "1",
pages = "41-45",
doi = "10.2478/v10011-008-0029-9"
}

Beletić, A., Mirković, D., Antonijević, N., Đorđević, V., Sango, V., Jakovljević, B., Perunicić, J., Ilić, M., Vasiljević, Z.,& Majkić-Singh, N.. (2009). Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 28(1), 41-45.
https://doi.org/10.2478/v10011-008-0029-9

Beletić A, Mirković D, Antonijević N, Đorđević V, Sango V, Jakovljević B, Perunicić J, Ilić M, Vasiljević Z, Majkić-Singh N. Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction. in Journal of Medical Biochemistry. 2009;28(1):41-45.
doi:10.2478/v10011-008-0029-9 .

Beletić, Anđelo, Mirković, Duško, Antonijević, Nebojša, Đorđević, Valentina, Sango, Violeta, Jakovljević, Branko, Perunicić, Jovan, Ilić, Mirka, Vasiljević, Zorana, Majkić-Singh, Nada, "Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction" in Journal of Medical Biochemistry, 28, no. 1 (2009):41-45,
https://doi.org/10.2478/v10011-008-0029-9 . .